Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
06 févr. 2019 08h30 HE
|
Eyenovia, Inc.
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
30 janv. 2019 07h00 HE
|
Eyenovia, Inc.
MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform delivery technology ...
Eyenovia Prices Public Offering of Common Stock
19 déc. 2018 09h05 HE
|
Eyenovia, Inc.
NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose...
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
03 déc. 2018 09h00 HE
|
Eyenovia, Inc.
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study and enrolled the first patient in its...
Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability
28 nov. 2018 16h05 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high...
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
26 nov. 2018 09h00 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis
13 nov. 2018 07h30 HE
|
Eyenovia, Inc.
Company on track to initiate Phase III trials in late November NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of...
Eyenovia Reports Third Quarter 2018 Financial Results
13 nov. 2018 06h30 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Announces Conference Call and Webcast for Third Quarter 2018 Financial Results
01 nov. 2018 08h30 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2018
23 oct. 2018 09h00 HE
|
Eyenovia, Inc.
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...